

(Translation)

September 24, 2026

Company name:	Riken Vitamin Co., Ltd.
Name of representative:	Tsutomu Mochizuki President and Representative Director (Securities code: 4526; Tokyo Stock Exchange Prime Market)
Inquiries:	Yoshiya Inoue General Manager of IR & PR Department (Tel: 03-5362-1315)

Notice Regarding the Status and Completion of Acquisition of Own Shares

Riken Vitamin Co., Ltd. (the "Company") hereby announces the status of the acquisition of its own shares pursuant to Article 156 of the Companies Act, as applied pursuant to Article 165(3) of the Companies Act, as resolved at the meeting of its Board of Directors held on May 13, 2026, as follows. The Company also announces the completion of the acquisition of its own shares pursuant to the above resolution of the Board of Directors.

1. Class of shares acquired	Common stock
2. Total number of shares acquired	111,700 shares
3. Total amount of share acquisition cost	370,159,496 yen
4. Period of acquisition	From September 1, 2026 to September 18, 2026
5. Method of acquisition	Market purchase on the Tokyo Stock Exchange

(Reference)

1. Details of the resolution at the Board of Directors meeting held on May 13, 2026

(1) Class of shares to be acquired	Common stock
(2) Total number of shares to be acquired	900,000 shares (Upper limit) (3.08% of the total number of shares issued excluding treasury shares)
(3) Total amount of share acquisition cost	2,000,000,000 yen (Upper limit)
(4) Period of acquisition	From June 1, 2026 to September 30, 2026
(5) Method of acquisition	Market purchase on the Tokyo Stock Exchange

2. Cumulative total of own shares acquired based on the above resolution (as of September 18, 2026)

(1) Total number of shares acquired	634,300 shares
(2) Total amount of share acquisition cost	1,999,927,975 yen